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Abstract
A dual-action cyclooxygenase (COX) - fatty acid amide hydrolase (FAAH) inhibitor may have
therapeutic usefulness as an analgesic, but a key issue is finding the right balance of inhibitory
effects. This can be done by the design of compounds exhibiting different FAAH/COX inhibitory
potencies. In the present study, eight ibuprofen analogues were investigated. Ibuprofen (1), 2-(4-
Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide (9) and N-(3-
methylpyridin-2-yl)-2-(4′-isobutylphenyl)propionamide (2) inhibited FAAH with IC50 values of
134, 3.6 and 0.52 μM respectively. The corresponding values for COX-1 were ~29, ~50 and ~60
μM, respectively. Using arachidonic acid as substrate, the compounds were weak inhibitors of
COX-2. However, when anandamide was used as COX-2 substrate, potency increased, with
approximate IC50 values of ~6, ~10 and ~19 μM, respectively. 2 was confirmed to be active in
vivo in a murine model of visceral nociception, but the effects of the compound were not blocked
by CB receptor antagonists.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (1, Figure 1) are used
widely for the treatment of pain. The primary mechanism of action of NSAIDs, inhibition of
prostaglandin production by cyclooxygenase (COX) enzymes, has been known for almost
forty years.1 However, their use is associated with an unacceptably high incidence of
gastrointestinal and cardiovascular adverse events, resulting in the need for safer NSAIDs.
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In 2009, it was reported that blockade of fatty acid amide hydrolase, the enzyme responsible
for the hydrolysis of the endogenous cannabinoid receptor ligand anandamide
(arachidonoyletholamide, AEA), reduced by almost an order of magnitude the dose of the
NSAID diclofenac required to produce analgesia in a model of visceral pain.2 The authors
also demonstrated that the combination of an FAAH inhibitor* (or genetic deletion of the
enzyme) and diclofenac was less ulcerogenic than the NSAID alone.2 The authors concluded
that ”a combination of FAAH inhibitors and NSAIDs may have great utility to treat visceral
pain, with reduced gastric toxicity”.2
A disadvantage of treatment with a combination of drugs, either given separately or as a
multicomponent formulation, is that different rates and variabilities in metabolism of the two
component compounds can lead to a very wide variation in delivered dosages and thereby
variation in treatment outcome.3 An alternative approach, termed “designed multiple
ligands”, is the use of compounds with efficacy towards both targets.3 This is advantageous
inasmuch as the pharmacokinetic issues are resolved, but of course the main issue is
obtaining optimal balance of actions towards the two targets. One way of addressing this
approach is the design of compounds exhibiting different relative potencies towards the two
targets in question. Such compounds can be used in predictive models to identify the ideal
ratio of activities, which can then form the basis of design and choice of lead compound(s)
for pharmaceutical development.
Ibuprofen, like other acidic NSAIDs, is a weak inhibitor of FAAH.4,5 In 2007, we reported
that the ibuprofen analogue N-(3-methylpyridin-2-yl)-2-(4′-isobutylphenyl)-propionamide
(ibu-am5, 2, Fig. 1) was 2–3 orders of magnitude more potent as an inhibitor of FAAH than
ibuprofen, but retained its COX inhibitory properties, as assessed using a simple COX assay
kit.6 This dual-activity raises the possibility that novel compounds related to ibuprofen and
ibu-am5 may, together with these two compounds, provide structures with different FAAH/
COX inhibitory potencies for achieving the ideal balance of effects in vivo. Consequently in
the present study we designed novel compounds related to 1 and 2, and investigated their
activity with respect to their FAAH-inhibitory potencies. The best novel derivative as well
as 1, 2 were further investigated with respect to their COX-inhibitory potencies using an
oxygen electrode assay using arachidonic acid (COX-1 and -2) and anandamide (COX-2) as
substrates. The endocannabinoid component of the effect of 2 was also investigated in vivo
using a murine visceral pain model.
Materials and Methods
Materials
Anandamide [ethanolamine-1-3H] (specific activity 2.22 TBq mmol-1) was purchased from
American Radiolabeled Chemicals, Inc (St. Louis, MO). Ovine COX-1 (cat. no. 60100),
human recombinant COX-2 (cat. no. 60122), arachidonic acid and non-radioactive
anandamide were obtained from the Cayman Chemical Co (Ann Arbor, MI, USA).
Rimonabant (CB1 receptor antagonist) and SR144528 (CB2 receptor antagonist) were
obtained from NIDA (Rockville, MD).
Chemistry
Melting points were determined on a Stuart Scientific Melting point SMP1 and are
uncorrected. Proton NMR spectra were recorded on a Varian Unity 300 spectrometer. The
chemical shift are reported in part per million (δ, ppm) downfield from tetramethylsilane
*linguistic note: whether to write “an FAAH” or “a FAAH” is dependent upon whether FAAH is considered as an abbreviation (i.e. F-
A-A-H, where the F is pronounced “ef”) or a word (where the F is pronounced as f). In this paper, the abbreviation is used.
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(TMS), which was used as internal standard. Infrared spectra were obtained with a Bruker
Vector 22 spectrophotometer. Elemental analyses were carried out with a Carlo Erba model
1106 Elemental Analyzer and the values found were within 0.4% of theoretical values.
Analytical thin layer chromatography (TLC) was carried out on E. Merck TLC plates coated
with silica gel 60 F254 (0.25mmlayer thickness). TLC visualization was carried out using an
UV lamp. Ibuprofen and all reagents and solvents were purchased from the Sigma Chemical
Co (St. Louis, MO, USA). Ibu-am5 was synthesised as described previously.7
Synthesis of 3-methylpyridin-2-yl 2-(4-isobutylphenyl)propanoate (3)—CDI
(0.39 g, 2.4 mmol) was added to a solution of 1 (0.41 g, 2 mmol) in 10 mL of
dichloromethane. After the reaction mixture was stirred at r.t. for 30 min 2-idroxy-3-
methylpyridine (0.22 g, 2 mmol) was added and the reaction mixture was heated at reflux
until disappearance of starting material detected by analytical TLC (72 h). After cooling the
dichloromethane solution was washed consecutively with water, saturated sodium hydrogen
carbonate and water. The organic layer was dried over sodium sulfate, filtered, and
concentrated in vacuo. The residue was triturated with isopropyl ether to give title
compound which was isolated by filtration and air dried. Yield 54%; mp 40–42 °C ; 1H
NMR (DMSO-d6) δ 0.91 (d, J=6.6, 6H), 1.30 (t, J=7.8, 3H), 1.56 (d, J= 7.0, 2H), 1.82 (m,
1H), 2.20 (s, 3H), 3.78 (m, 1H), 6.27, 7.13, 7.19, 7.30, 7.35 (m, 7H). IR (nujol) 3146, 1733,
1642 cm−1. Anal. Calcd for C19H23N2O: C, 76.74; H, 8.70; N, 4.71. Found: C, 76.80; H,
8.68; N, 4.74.
General procedure for the preparation of compounds 4, 5
A mixture of 1 (2 mmol), EDC (0.39 g, 2.2 mmol), and HOBt (0.27 g, 2 mmol) in dry
MeCN (10 mL) was stirred at room temperature. After 30 min TEA (0.4 mL, 4 mmol) and
glycine ethyl ester hydrochloride (0.56 g, 4 mmol) or ethyl 3-aminopropanoate (0.61 g, 4
mmol) were added. The mixture was stirred at room temperature for an additional 4 h. Then
the solution was evaporated to dryness in vacuo. The residue was dissolved in ethyl acetate
(20 mL) and washed with brine (2× 5 mL), 10% aqueous hydrochloric acid (2× 5 mL), 5%
aqueous sodium hydroxide (2× 5 mL), and water (2× 5 mL). The organic layer was dried
over anhydrous magnesium sulfate. Concentration of the dried extract yielded a residue
which was triturated with isopropyl ether. The formed precipitate was filtered off and
purified by crystallization from the adequate solvent to give derivatives 4, 5.
Ethyl 2-(4-isobutylbenzamido)acetate (4)—Yield 70%; mp 132–133 °C (2-PrOH); 1H
NMR (DMSO-d6) δ 0.91 (d, J=6.6, 6H), 1.30 (t, J=7.8, 3H), 1.52 (d, J= 7.0, 2H), 1.82 (m,
1H), 2.18 (m, 2H), 2.43 (m, 1H), 3.52 (m, 1H), 4.13 (q, J=7.8, 2H), 4.16 (s, 2H), 7.13 (m,
2H), 7.30 (m, 2H), 8.35 (s, 1H). IR (nujol) 3230, 2766, 1712, 1653 cm−1. Anal. Calcd. for
C17H25NO3: C, 70.07; H, 8.65; N, 4.81. Found: C, 70.01; H, 8.66; N, 4.84.
Ethyl 3-(4-isobutylbenzamido)propanoate (5)—Yield 85%; mp 128–130 °C (2-
PrOH); 1H NMR (DMSO-d6) δ 0.92 (d, J=6.6, 6H), 1.28 (t, J=7.8, 3H), 1.49 (d, J= 7.0, 2H),
1.82 (m, 1H), ), 2.19 (m, 2H), 2.40 (m, 1H), 2.65 (m, 2H), 3.52 (m, 1H), 4.12 (q, J=7.8, 2H),
4.15 (s, 2H), 7.17 (m, 2H), 7.33 (m, 2H), 8.32 (s, 1H). IR (nujol) 3244, 2754, 1718, 1647
cm−1. Anal. Calcd. for C18H27NO3: C, 70.79; H, 8.91; N, 4.59. Found: C, 70.84; H, 8.88; N,
4.56.
General procedure for the synthesis of acids 6 and 7
To a solution of 4, 5 (1 mmol) in ethanol (10 mL) 50% aqueous sodium hydroxide (2 mL)
and water (2 mL) were added. The mixture was stirred at room temperature for 24 h. The
mixture was concentrated in vacuo and then ice was added. Then the solution was acidified
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with 20% aqueous hydrochloric acid to pH 3–4. The formed solid was filtered off, washed
with water, air-dried, and crystallized from ethanol to give compounds 6 and 7.
2-(2-(4-isobutylphenyl)propanoylamino)acetic acid (6)—Yield 76%; mp 160–161
°C (2-PrOH); 1H NMR (DMSO-d6) δ 0.91 (d, J=6.6, 6H), 1.52 (d, J= 7.0, 2H), 1.82 (m,
1H), 2.19 (m, 2H), 2.43 (m, 1H), 3.52 (m, 1H), 4.14 (s, 2H), 7.13 (m, 2H), 7.30 (m, 2H),
8.35 (s, 1H), 10.82 (s, 1H). IR (nujol) 3317, 1770, 1661 cm−1. Anal. Calcd. for C15H21NO3:
C, 68.42; H, 8.04; N, 5.32. Found: C, 68.37; H, 8.06; N, 5.35.
3-(2-(4-isobutylphenyl)propanoylamino)-propanoic acid (7)—Yield 84%; mp 147–
149 °C (2-PrOH); 1H NMR (DMSO-d6) δ 0.91 (d, J=6.5, 6H), 1.52 (d, J= 6.9, 2H), 1.84 (m,
1H), 2.19 (m, 2H), 2.42 (m, 1H), 2.66 (m, 2H), 3.52 (m, 1H), 4.16 (s, 2H), 7.17 (m, 2H),
7.35 (m, 2H), 8.40 (s, 1H), 10.78 (s, 1H). IR (nujol) 3307, 3061, 1698, 1643 cm−1. Anal.
Calcd. for C16H23NO3: C, 69.29; H, 8.36; N, 5.05. Found: C, 69.24; H, 8.38; N, 5.02.
Synthesis of 4-acetamidophenyl 2-(2-(4-isobutylphenyl)propanamido)acetate
(8)—A mixture of the acid 6 (0.28 g, 1 mmol), EDC (0.19 g, 1.1 mmol), and HOBt (0.13 g,
1 mmol) in dry MeCN (10 mL) was stirred at room temperature for 30 min and then treated
with paracetamol (0.15g, 1 mmol). The mixture was stirred at room temperature for an
additional 24 h. Then the solution was evaporated to dryness in vacuo. The residue was
dissolved in ethyl acetate (20 mL) and washed sequentially with brine (2 × 5 mL), 5%
aqueous sodium hydroxyde (2 × 5 mL), and water (2 × 5 mL). The organic layer was dried
over anhydrous magnesium sulfate. Concentration of the dried extracts yielded the title
compound in analytically pure form. Yield 58%; mp 94–97 °C; 1H NMR (DMSO-d6) δ 0.96
(d, J=6.3, 6H), 1.45 (d, J=6.9, 3H), 1.91 (m, 1H), 2.14 (s, 3H), 2.20 (s, 2H), 3. 43 (m, 1H),
4.18 (s, 2H), 7.10, 7.20, 7.33, 7.68 (m, 7H), 8.62 (d, J=5.8 Hz, 1H), 8.34 (s, 1H), 10.13 (s,
1H). IR (nujol) 3307, 1779, 1669, 1650 cm−1. Anal. Calcd. for C23H28N2O4: C, 69.68; H,
7.12; N, 7.07. Found: C, 69.64; H, 7.10; N, 7.04.
General procedure for the preparation of ibuprofen amides (9–13)
A mixture of the appropriate acid 6, 7 (1 mmol), EDC (0.19 g, 1.1 mmol), and HOBt (0.13
g, 1 mmol) in dry MeCN (10 mL) was stirred at room temperature for 30 min and then
treated with the appropriate amine (1 mmol). The mixture was stirred at room temperature
for an additional 24 h. Then the solution was evaporated to dryness in vacuo. The residue
was dissolved in ethyl acetate (20 mL) and washed sequentially with brine (2·5 mL), 10%
aqueous sodium carbonate (2·5 mL), 10% aqueous citric acid (2·5 mL), and water (2·5 mL).
The organic layer was dried over anhydrous magnesium sulfate. Concentration of the dried
extracts yielded amides 9–13 in analytically pure form without additional purification if not
indicated otherwise.
2-(4-Isobutylphenyl)-N-(2-(3-methylpyridin-2-ylamino)-2-oxoethyl)propanamide
(9, ibu-am14)—Yield 68%; oil; 1H NMR (DMSO-d6) δ 0.95 (d, J=6.6, 6H), 1.45 (d, J=7.0,
3H), 1.90 (m,1H), 2.14 (s, 2H), 2.20 (s, 3H), 2.50 (s, 3H), 3.60 (m, 1H), 4.04 (m, 2H), 7.19,
7.30, 7.40, 7.74 (m, 7H), 8.34 (s, 1H), 10.05 (s, 1H). IR (nujol) 3264, 1660 cm−1. Anal.
Calcd. for C21H27N3O2: C, 71.36; H, 7.70; N, 11.89. Found: C, 71.41; H, 7.68; N, 11.93.
2-(4-Isobutylphenyl)-N-(2-(6-methylpyridin-2-ylamino)-2-oxoethyl)propanamide
(10)—Yield 55%; mp 121–123 °C (Cyclohehane); 1H NMR (DMSO-d6) δ 0.96 (d, J=6.3,
6H), 1.44 (d, J=6.9, 3H), 1.92 (m, 1H), 2.42 (m, 2H), 2.50 (s, 3H), 3.54 (m, 1H), 4.10 (s,
2H), 7.07, 7.19, 7.35, 7.77, 7.93 (m, 7H), 8.44 (d, J=5.8 Hz, 1H), 8.34 (s, 1H), 10.43 (s, 1H).
IR (nujol) 3284, 3069, 1682, 1645 cm−1. Anal. Calcd. for C21H27N3O2: C, 71.36; H, 7.70;
N, 11.89. Found: C, 71.30; H, 7.72; N, 11.86.
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2-(4-Isobutylphenyl)-N-(3-(3-methylpyridin-2-ylamino)-3-
oxopropyl)propanamide (11)—Yield 62%; oil; 1H NMR (CDCl3) δ 0.85 (d, J=5.5, 6H),
1.45 (d, J=7.3, 3H), 1.79 (m, 1H), 2.14 (m, 1H), 2.42 (m, 2H), 2.48 (m, 2H), 2.70 (m, 2H),
3.50 (m, 3H), 6.98–7.78 (m, 7H), 8.11 (s, 1H), 9.13 (s, 1H). IR (nujol) 3307, 1779, 1669,
1650 cm−1. Anal. Calcd. for C22H29N3O2: C, 71.90; H, 7.95; N, 11.43. Found: C, 71.96; H,
7.92; N, 11.45.
2-(4-Isobutylphenyl)-N-(2-oxo-2-(pyridin-2-ylmethylamino)ethyl)propanamide
(12)—Yield 68%; mp oil; 1H NMR (DMSO-d6) δ 0.95 (d, J=6.5, 6H), 1.44 (d, J=7.0, 3H),
1.89 (hept, J=6.5, 1H), 2.49 (m, 2H), 3.54 (m, 1H), 4.10 (s, 2H), 4.48 (m, 2H), 7.16, 7.40,
7.88, 8.37, 8.50 (m, 8H), 8.60 (s, 1H), 10.45 (s, 1H). IR (nujol) 3320, 1704, 1672, 1645
cm−1. Anal. Calcd. for C21H27N3O2: C, 71.36; H, 7.70; N, 11.89. Found: C, 71.43; H, 7.71;
N, 11.85.
2-(4-Isobutylphenyl)-N-(2-oxo-2-(pyridin-3-ylmethylamino)ethyl)propanamide
(13)—Yield 75%; oil; 1H NMR (CDCl3) δ 0.84 (d, J=5.9, 6H), 1.41 (d, J=6.5, 3H), 1.92
(sept, J=6.5, 2H), 2.38 (t, J=7.2, 2H), 3.56 (m, 1H), 4.14 (s, 2H), 4.32 (s, 2H), 7.3, 7.13,
7.27, 7.65 (m, 8H), 8.43 (s, 1H), 8.47 (s, 1H). IR (nujol) 3298, 3069, 1692, 1654 cm−1.
Anal. Calcd. for C21H27N3O2: C, 71.36; H, 7.70; N, 11.89. Found: C, 71.31; H, 7.73; N,
11.94.
FAAH assay
Frozen (−80 °C) brains (minus cerebella) from adult Wistar or Sprague-Dawley rats were
thawed and homogenised in 20 mM HEPES, 1 mM MgCl2, pH 7.0. and thereafter
centrifuged at ~35000 × g for 20 min at 4 °C. Homogenates were washed (by centrifugation
at ~35000 × g for 20 min at 4 °C followed by resuspension in buffer) twice and incubated at
37 °C for 15 minutes in order to hydrolyse all endogenous FAAH substrates. After a further
centrifugation, the pellets were resuspended in 50 mM Tris-HCl buffer, pH 7.4, containing 1
mM EDTA and 3 mM MgCl2 and frozen at −80 °C in aliquots until used for assay. For
FAAH assay8 test compounds, homogenates (0.5–0.8 μg protein per assay, diluted with 10
mM Tris-HCl, 1 mM EDTA pH 7.4) and 25 μL of [3H]AEA in 10 mM Tris- HCl, 1 mM
EDTA, pH 7.4, containing 1% w/v fatty acid-free bovine serum albumin, final substrate
concentration of 0.5 μM) were incubated for 10 min at 37 °C (final assay volume 200 μL).
Reactions were stopped by placing the tubes on ice. Final assay concentrations of the
solvents used for the compounds (ethanol or DMSO) were in the range 1–5%. Activated
charcoal (80 μL + 320 μL 0.5 M HCl) was added and the samples were mixed and left at
room temperature for about 30 min. Following centrifugation at 2500 rpm for 10 min,
aliquots (200 μL) of the supernatants were analyzed for titrium content by liquid
scintillation spectroscopy with quench correction. Blank values were obtained by the use of
buffer rather than homogenate.
COX assay
An assay based on the oxygen electrode method of Meade et al.9 was used.10 A buffer
containing 1 μM hematin, 2 mM phenol, 5 mM EDTA, substrate (AA or AEA, 10 μM, as
indicated) and 0.1 M tris-HCl, pH 7.4 (final assay volume 2 mL) at room temperature was
added to an oxygen electrode chamber with an integral stirring unit (Oxygraph System,
Hansatech Instruments, King’s Lynn, U.K.) that had been calibrated with respect to air
pressure and ambient temperature. After addition of test compound dissolved in vehicle
(DMSO or ethanol, as indicated, 20 μL), a baseline was established over a period of 5 min.
Reactions were started by addition of the appropriate COX isoform (200 U per assay,
usually in a volume of 8–15 μL), and the oxygen consumption was followed for the next 5
min. Data are presented as the change in oxygen consumption (μM) from the point of
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addition of the enzyme. We regard this assay as more “robust” than the assay kit we used
previously6, simply because the oxygen electrode assay has been very well characterised in
the literature with respect to effects of NSAIDs9, whereas the kit used in our previous study6
measured the peroxidase activity of COX and was characterised by the manufacturers with
respect to sensitivity to two experimental compounds (SC-560 for COX-1, DuP-697 for
COX-2) rather than towards NSAIDs.
Acetic acid-induced abdominal stretching test
Male C57Bl/6J mice (Jackson Laboratory, Bar Harbor, ME) weighing between 20 and 25 g
and were housed four mice per cage in a temperature-controlled (20–22 °C) facility, with
food and water available ad libitum. All animals were acclimatized to the laboratory
environment for at least 2 h before testing and the acetic acid-induced stretching assay was
carried out as previously described.11 In brief, mice were injected intraperitoneally with 10
ml/kg of 0.6 % acetic acid in normal saline and the number of stretches (constriction of
abdomen, turning of trunk (twist) and extension of the body and hind limbs) per mouse was
counted for a 20-min period beginning 3 min after the administration of acetic acid. Mice
were given s.c. injections of 2 (30 mg/kg) 30 min before acetic acid. The cannabinoid
receptor antagonists were given s.c. 10 min before 2. All the drugs were dissolved in a
vehicle consisting of ethanol, alkamuls-620 (Rhone-Poulenc, Princeton, NJ), and saline in a
ratio of 1:1:18. The drugs were administered in a volume of 10 μl/g body weight. All animal
protocols were approved by the Virginia Commonwealth University Institutional Animal
Care and Use Committee and were in concordance with the National Institutes of Health
guide for the care and use of Laboratory animals.
Statistical analyses
For determinations of pI50 and IC50 values, the GraphPad Prism computer programme
(GraphPad Software Inc., San Diego, CA) was used. The built-in programme “sigmoidal
dose-response (variable slope)” calculated pI50 and hence IC50 values from the data
expressed as % of control using top (i.e. uninhibited) values of 100% and bottom (residual
activity) values that were either set to zero or allowed to float. The two curves were
compared using Akaike’s informative criteria and the curve of best fit was then used. In vivo
data were analyzed by two-way ANOVA, with agonist (vehicle or 2) and antagonist
(vehicle, rimonabant, or SR144528), as the two factors.
Results
Synthesis of ibuprofen analogues
The chemistry work was undertaken in the laboratory of Onnis and Congiu. The target ester
and amides of ibuprofen (Table 1) were synthesized as reported in Schemes 1 and 2.
Treatment of 1 with 2-hydroxy-3-methylpyridine in the presence of 1,1-carbonyldiimidazole
(CDI) in CH2Cl2 solution gave ester 3 Ibuprofen was coupled with glycine ethyl ester or
ethyl 3-aminopropanoate, in the presence of 1-(3-dimethylaminopropyl)-3-
ethylcardodiimide hydrochloride (EDC) and hydroxybenzotriazole (HOBt) in MeCN
solution, followed by hydrolysis to give 2-(2-(4-isobutylphenyl)propanoylamino)acetic acid
(6) and 3-(2-(4-isobutylphenyl)propanoylamino)propanoic acid (7) respectively. The ester 8
was obtained by reaction of acid 6 with paracetamol by EDC method. Similarly, the amide
derivatives 9–13 were obtained coupling the acids 6,7 with the appropriate 2-aminopyridine
or picolylamine. This synthetic pathway was found to be clean and high yielding.
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Pharmacological studies
FAAH inhibition—The in vitro pharmacology studies were undertaken in the laboratory of
Fowler and Björklund. The ability of compounds 3, 8–13, with 1 and 2 as references, to
inhibit FAAH activity was determined using 0.5 μM [3H]AEA as substrate and rat brain
homogenates as enzyme source (Table 1). Since some of the compounds used DMSO and
others ethanol as vehicle, compounds 1 and 2 were tested in both vehicles, with very similar
results (Table 1). Consistent with our previous data,6 2 was approximately 250-fold more
potent than 1 as an FAAH inhibitor (Table 1). This increase in potency was completely lost
when the amido moiety of 2 was replaced with an ester moiety (ester 3, Table 1).
Introduction of an extra three/four atom linker between ibuprofen core and pyridine ring or
esterification with paracetamol did not improve FAAH inhibitory potency with respect to 2.
However, the paracetamol ester (8) and the analog bearing an extra three atom linker (ibu-
am14, 9) had IC50 values in the low micromolar range, with 9 being approximately 40-fold
more potent than 1 (Table 1). Concentration-response curves for 1, 2 and 9 are shown in
Figure 2A.
Of the novel compounds, the two most potent were 8 and 9. However, compound 8 did not
produce a complete inhibition of the FAAH activity, and so 9 was chosen for further
investigation. The compound did not show time-dependent inhibition of FAAH (Figure 2B),
suggesting that it interacts in a non-covalent manner with the enzyme and that the compound
is stable during the preincubation period. In experiments undertaken with ten AEA
concentrations (0.3–3 μM; Figure 2C), the mean Kmapp values in the presence of 0, 1, 3 and
5 of 9 were 0.56, 1.18, 2.04 and 2.56 μM, respectively. The corresponding Vmaxapp values
were 2.09. 2.32, 2.42 and 2.40 nmol.mg protein−1.min−1, respectively, with overlapping
95% confidence intervals, i.e. a competitive mode of inhibition. A secondary replot of
Kmapp/Vmaxapp vs. [9] gave a Ki value of 2.0 μM.
The reversibility of 9 was investigated by dilution experiments. In these experiments, 9 (12
μM) was preincubated with homogenates for 60 min at 37 °C, and the homogenates were
then diluted 20-fold in buffer. The inhibition produced by 9 was thereafter compared with
concomitant data where 9 (0.6 or 12 μM) was added after the preincubation phase. For a
fully reversible compound, the inhibition produced by 12 μM prior to dilution (shown as 12
→ 0.6 in Figure 2D) should be the same as that produced by 0.6 μM added after the
inhibition. For a non-reversible inhibitor, on the other hand, the inhibition seen with 12 →
0.6 μM should be greater than seen with 0.6 μM and closer to that produced by 12 μM
added after the preincubation phase. The data shown in Figure 2D indicates that 9 is fully
reversible. Experiments were also undertaken using 6 μM (and 6 → 0.3 μM) of 9, but in
this case the observed inhibition with 9 was lower than expected from the concentration-
response experiments and conclusions with respect to reversibility at this concentration
could not be made (data not shown).
COX inhibition
Given that our original study with 2 used a kit for estimation of COX activity based upon the
peroxidase rather than cyclooxygenase activity of the enzyme,6 the present study employed
a more robust measure of inhibitory potency. Consequently 1 and 2 were tested together
with 9 using an oxygen electrode assay for COX, with commercially available ovine COX-1
and human recombinant COX-2 as enzyme sources. Arachidonic acid (AA) was used as
substrate for both forms. COX-2 was also assayed using AEA as substrate in view of a
recent report that the inhibitory potency of 1 towards COX-2 is dependent upon the substrate
used for assay.12 AEA is not a substrate for COX-1, and so this combination was not tested.
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The results, with ethanol as vehicle, are shown in Figure 3. As expected, 1 inhibited the
activity of ovine COX-1 towards AA (10 μM). The initial activites (between 10 and 30 s
after addition of COX isoform) determined from the data shown in Fig. 3A and from
additional experiments, expressed as % of vehicle control, are summarised in Table 2. The
number of concentrations that could be tested was constrained both by assay capacity and
particularly assay cost, and so only approximate IC50 values can be determined. With this
caveat, an IC50 value of ~29 μM was found for 1. A slightly lower potency was seen when
DMSO was used as vehicle for 1 (IC50 value ~77 μM). Compound 2 was less potent than 1
with respect to COX-1, with an IC50 value of ~60 μM being found with ethanol as vehicle
and ~240 μM with DMSO as vehicle. Compound 9 inhibited COX-1 with an IC50 value of
~50 μM (ethanol vehicle). 1 (as expected), 2 and 9 were poor inhibitors of the
cyclooxygenation of AA by COX-2, producing 36, 41 and 18% inhibition at the highest
concentrations tested (300, 300 and 100 μM, respectively). However, when AEA was used
as substrate, the compounds were potent inhibitors of COX-2, with IC50 values of ~6, ~19
and ~10 μM being found for 1, 2 and 9, respectively (Figure 3, Table 2). Experiments with
flurbiprofen indicated that a similar pattern of substrate selectivity was seen, indicating that
it is not a phenomenon limited to ibuprofen and ibuprofen analogues alone (data not shown).
Effect of cannabinoid receptor blockade on the in vivo activity of compound 2 in a mouse
model of visceral nociception
The in vivo studies were undertaken in the laboratory of Lichtman and Naidu. Compound 2
was chosen for three reasons: 1) The compound was the most potent of the series towards
FAAH; 2) Sufficient compound was available for in vivo studies (not the case for compound
9); 3) We have previously shown that 2 at doses of 10 and 30 mg/kg s.c. (mice) and 20 mg/
kg i.p. (rats) has analgesic activity in the acetic acid-induced abdominal stretching test.7,13
but it is not known whether this effect involves activation of cannabinoid receptors. We
investigated this here using the CB1 receptor antagonist rimonabant and the CB2 receptor
antagonist SR144528. The doses chosen block CB receptor-mediated effects of FAAH
inhibition or genetic ablation in vivo in mice.2,14,15 The data in Figure 4 indicate that
although 2 decreased the number of abdominal stretches at the 30 mg/kg dose [F(1,42) =
72.7, p < 0.0001], neither rimonabant nor SR144528 diminished these antinociceptive
effects.
Discussion
In the present study, we have explored compounds related to 1 with respect to their FAAH-
inhibitory properties, and compared 1, 2 and 9 with respect to their actions upon COX
isoforms. An in vivo investigation of 2 in a visceral pain model has also been presented. The
main results are discussed in turn below.
Compounds with different FAAH/COX inhibitory ratios have been identified
Relatively little work has been undertaken upon the FAAH inhibitory properties of
ibuprofen analogues. In our initial study,6 we explored a series of heterocyclic amide
analogues of 1 and found that a 6-methyl-pyridin-2-yl substituent (compound 2) gave the
best activity, with the compound showing similar activity towards both rat and mouse
FAAH. More recently, a 1,3-dithian-2-yl derivative of 1 has been described with a potency
towards FAAH in the low micromolar region.16 This compound, which was almost two
orders of magnitude more potent than its analogue lacking the 4-isobutyl substituent on the
phenyl ring, showed anti-inflammatory activity in an in vitro model (interleukin-1μ
stimulated interleukin-8 secretion from Caco-2 cells).16 The ability of the compound to
interact with COX enzymes, however, is not known. Finally, 4-acetamidophenyl 2-(4-(2-
(trifluoromethyl)pyridin-4-ylamino)phenyl)propanoate in which the carboxyl moiety of 1 is
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esterified with paracetamol and a 2-(trifluoromethyl)pyridin-4-ylamino replaced the
isobutyryl chain was a very potent inhibitor of FAAH (IC50 value of 0.1 μM). However, this
compound did not inhibit either COX isoform.10
In the present study, we have not been able to improve upon the potency of 2. Although this
at first sight might be considered a limitation of the importance of the study, this is not in
fact the case: the main aim, to produce dual-action compounds with different FAAH/COX
potencies, has been achieved. Compound 9 shares with 1 and 2 a mode of inhibition that is
not time-dependent. However 9 is a competitive inhibitor of rat brain AEA hydrolysis
whereas 1 is a mixed-type inhibitor3 and 2 acts non-competitively.6 These observations
would suggest that the compounds interact differently with the enzyme dependent upon the
nature of the substituent of ibuprofen carboxyl moiety. This suggestion may in turn help to
provide an explanation for the lack of activity of the ester (compound 3): given that FAAH
can metabolise both amides (such as AEA) and esters (such as 2-aracyidonoylglycerol17),
activity of 3 might have been expected.
Since FAAH and COX assays use different assay conditions, it is difficult to compare
potencies directly. However, the approximate ratio of potencies of FAAH/COX-1 can be
compared between compounds. Using this ratio and setting the FAAH/COX-1 ratio for 1 to
unity, the ratios for 2 and 9 are ~500 and ~60, respectively, where the higher number reflects
increased FAAH inhibitory potency relative to the COX-1 potency. In other words, 1, 2 and
9 cover a wide range of FAAH inhibitory potencies relative to the COX-1 inhibitory
potencies. A similar pattern is seen for COX-2 when assayed with AEA as substrate.
AEA cycloxygenation by COX-2 is more sensitive to 1, 2 and 9 than AA cyclooxygenation
When using AA as substrate, compounds 1 (as expected), 2 and 9 were clearly COX-1
selective. The difference in potency seen with ethanol and DMSO vehicles may reflect the
way the lipophilic inhibitor presents itself to COX in the assay buffer – vehicle mixture.
Whatever the reason, it underscores the need to use the same vehicle when comparing COX
inhibitory potencies of different compounds. All three compounds were more potent as
inhibitors of AEA cyclooxygenation by COX-2 than of AA cyclooxygenation by either
COX isoform. Thus, for example, at a concentration of 10 μM, 1 produced a 19% inhibition
of COX-1, but a 64% inhibition of AEA cyclooxygenation by COX-2, whilst a 100 μM
concentration of this NSAID produced only 13% inhibition of COX-2 activity with
arachidonic acid as substrate. Given that the Km value of COX-2 towards AEA as substrate
is slightly higher than for AA,18 these data indicate a considerable substrate-dependency of
inhibition of COX-2. Our data are consistent with the recent finding that both 1 and other
COX inhibitors, including mefamic acid and naproxen, were also better inhibitors of the
cyclooxygenation of the other main endocannabinoid, 2-arachidonoylglycerol (2-AG) than
of AA.12,19 Indeed, even the R-enantiomers of 1, naproxen and flurbiprofen, were able to
inhibit COX-2-catalysed oxygenation of 2-AG, whereas these compounds do not inhibit the
cyclooxygenation of AA by this enzyme.19 Using site-directed mutagenesis and
crystallography, the authors showed that the R-profens interact with the Arg120 residue in
the COX-2 active site.19 COX-2 is a dimer, and although both monomers are capable of
oxygenating AA, the dimer displays half of sites reactivity, i.e. binding of AA to one
monomer precludes binding to the second monomer.20 Prusakiewicz et al.12 suggested that
in order to block AA oxygenation, the inhibitor needed to bind to both monomers, whereas
binding to a single monomer was sufficient for blockade of 2-AG oxygenation. Given that
the binding of AEA within the active site of COX-2 is different to that for AA,21,22 it is
reasonable to conclude that a similar mechanism may be operative here.
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The high sensitivity of COX-2 to ibuprofen with AEA as substrate, which was also seen
with flurbiprofen, together with the ability, albeit modest, of acidic NSAIDs (including R-
enantiomers) to inhibit FAAH,4,5,23,24 indicate that there is a considerable overlap in the
cyclooxygenase and endocannabinoid systems. This has also been seen in vivo in several
studies investigating the role of endocannabinoids in NSAID function. Thus, blockade or
genetic deletion of cannabinoid CB1 receptors: a) blocks the anti-nociceptive effects of
spinally administered indomethacin and flurbiprofen in the formalin test in rats,25,26 b)
blocks the effects of R-flurbiprofen upon heat hyperalgesia, mechanical hyperalgesia and
cold allodynia in the spared nerve injury model of neuropathic pain,24 c) antagonises the
effects of the COX-2 inhibitor L-745,337 (5-methanesulphonamido-6-(2,4-
difluorothiophenyl)-1-indanone) upon spinal hyperexcitability induced by knee joint
inflammation,27 and d) blocks the ability of spinally administered nimesulide to reduce
mechanically-evoked responses of dorsal horn neurons.28 In contrast, the analgesia produced
by diclofenac in the acetic acid-induced abdominal stretching model is not blocked by the
CB1 receptor antagonist rimonabant.2 Local injection into the paw of ibuprofen reduces the
second phase of the behavioural response to local formalin injection, and although this is not
blocked by a CB1 receptor antagonist/inverse agonist, the antinociceptive effect of the
combination of AEA and ibuprofen, which is greater than seen when either compound is
given per se, is entirely sensitive to CB1 receptor antagonist treatment.29 Treatment of
cultured dorsal root ganglia with inflammatory mediators, which results in an increased
COX-2 expression, causes them to release COX-2 derived products of AEA and 2-AG upon
ionomycin-stimulation, and that this is blocked (with a concomitant increase in
endocannabinoid levels) by R-profens.19 These findings led the authors to conclude that the
analgesic effects of R-flurbiprofen24 may be related to blockade of endocannabinoid
depletion by induced COX-2.19 Further studies are needed to determine the extent to which
inhibition of FAAH and of the cyclooxygenation of endocannabinoids by COX-2 contribute
to the in vivo observations described above.
The analgesic activity of Compound 2 in a visceral pain model is not blocked by CB
receptor antagonists
Previous data7,13 demonstrated that 2 is active in the acetic acid-induced abdominal
stretching test. In the rat, 2 at the dose of 20 mg/kg i.p. gave a significantly greater reduction
in stretching than the same dose of 1,7 whilst in the mouse, the effect of 30 mg/kg s.c. of 2
was greater than for a dose of 10 mg/kg s.c. and for 30 mg/kg of diclofenac.13 The acute
ulcerogenesis produced by 2 was also much lower than seen with 1.7 In order to determine
whether the activity of 2 in the mouse model involved the endocannabinoid system, we
investigated whether the CB1 receptor antagonist rimonabant or the CB2 receptor antagonist
SR144528 could block the response at doses known to be efficacious in this species.2,14,15
Neither compound produced any antagonism of the effect of 2. AEA itself can reduce acetic
acid-induced stretching in a rimonabant-sensitive manner, and the alternate endogenous
FAAH substrate palmitoylethanolamide is also active, in a manner blocked by SR144528,30
although the latter effect may reflect an off-target action of SR144528 upon peroxisome
proliferator-activated receptor-α.31 The reduction in the abdominal stretching response seen
in mice treated with potent FAAH inhibitors and in mice lacking FAAH compared to their
wild-type littermates is blocked by rimonabant but not SR144528.2 It is possible that at the
dose and in the model used, the contribution of analgesia due to the COX-inhibitory
properties of 2 dominates, and that the additional endocannabinoid-mediated component is
too small to detect. This pattern may not be the case in other pain models. A good analogy
of this scenario is the case of paracetamol that has been reported to produce an active
metabolite, AM404, which in turn acts both to inhibit the cellular accumulation and the
FAAH-catalysed breakdown of AEA as well as being an inhibitor of COX isoenzymes.32
The analgesic effects of paracetamol have been shown to have an endocannabinoid
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component (i.e. to be blocked by CB1 receptor antagonists) in some pain tests, such as the
formalin test,33 but not in the phenyl-p-quinone stretch test34 whereas both model systems
show endocannabinoid-mediated effects of FAAH inhibitors.34,35 An alternative explanation
is that in vivo, 2 is metabolised to a compound that retains (or even improves upon) its COX
inhibitory properties, but loses its efficacy towards inhibition of FAAH. Such a metabolite is
unlikely to be 1, given that in rats a dose of 20 mg/kg of 1 was significantly less effective
than 20 mg/kg of 2 in the abdominal stretching test.7 Clearly, further studies with this
compound, and with other ibuprofen analogues with different COX:FAAH inhibitory
properties, are needed in other pain model systems, particularly in those where NSAIDs
involve the endocannabinoid system in their effects.
Conclusions
The present study demonstrate that some heterocycle amide analogues of ibuprofen are a
useful source of compounds with biological activity in vivo and with varying FAAH/COX
inhibitory ratios, particularly with respect to the effects of the latter upon AEA
cyclooxygenation. Such compounds are of great potential value, given that they will prevent
loss of the increased AEA due to cyclooxygenation19 following FAAH inhibition. Although
an endocannabinoid component of 2 is not visible in a model of visceral pain, compounds 2
and 9, together with 1 may be useful tools with which to explore the optimum balance of
inhibitory effects in other experimental pain models.
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Figure 1.
Ibuprofen (1) and ibu-am5 (2)
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Figure 2.
Panel A. Concentration-response curves for the inhibition of rat brain [3H]AEA hydrolysis
by the compounds shown. Shown are means ± s.e.m. (when not enclosed by the symbols),
n=3–9. Panel B. Lack of dependency upon the preincubation time for the inhibition by 9 of
rat brain [3H]AEA hydrolysis. For each test concentration, one-way factorial ANOVA gave
a p value >0.05. Shown are means ± s.e.m., n=3. Panel C. Rates of AEA hydrolysis in the
absence and presence of 9 at ten different concentrations of AEA. Shown are means ±
s.e.m., n=3. Panel D. Reversibility of inhibition of rat brain [3H]AEA hydrolysis by 9.
Samples were preincubated for 60 min with either vehicle or the concentration shown of 9
and then diluted twenty-fold (shown as 12→0.6 in the Figure), after which substrate was
added and the samples were incubated for 10 min. Following the preincubation phase,
vehicle samples were either treated with vehicle or the concentrations of inhibitor shown.
The values are expressed as % of the vehicle control treated in the same way. Shown are
means and s.e.m., n=3.
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Figure 3.
Inhibition of ovine COX-1 and human recombinant COX-1 by A, 1; B, 2 and C, 9 The
substrates (10 μM) are shown in the figure, as are the concentrations (in μM) of the test
compounds. The vehicle used was ethanol. Shown are means and s.e.m. (when not enclosed
by the symbols), n=3.
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Figure 4.
Effects of the CB1 receptor antagonist rimonabant and the CB2 receptor antagonist
SR144528 upon the efficacy of 2 on the number of abdominal stretches elicited by acetic
acid. Vehicle or receptor antagonist (3 mg/kg s.c.) were given 10 min before either vehicle
or 2 (s.c.) and acetic acid was injected 30 min later. Data are depicted as means ± s.e.m., n=
8 mice/group.
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86
±2
2 
(ib
u-a
m5
)
Et
O
H
6.
28
±0
.0
1
0.
52
10
0
D
M
SO
6.
19
±0
.0
2
0.
65
10
0
3
Et
O
H
3.
94
±0
.0
3
11
5
10
0
8
Et
O
H
5.
83
±0
.0
5
1.
5
84
±3
9 
(ib
u-a
m1
4)
Et
O
H
5.
44
±0
.0
3
3.
6
10
0
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Ba
sic
 st
ru
ct
ur
e:
C
om
po
un
d
Su
bs
tit
ue
nt
 (R
)
So
lv
en
t
pI
50
a
IC
50
 
(μM
)
M
ax
 in
hi
bi
tio
n 
%
10
Et
O
H
3.
82
±0
.0
7
15
0
10
0
11
D
M
SO
5.
03
±0
.0
3
9.
3
90
±3
12
D
M
SO
4.
05
±0
.0
2
90
10
0
13
D
M
SO
4.
43
±0
.0
9
37
81
±8
a T
he
 in
hi
bi
to
r c
on
ce
nt
ra
tio
ns
 u
se
d 
to
 c
on
str
uc
t c
on
ce
nt
ra
tio
n-
re
sp
on
se
 c
ur
ve
s a
nd
 th
er
eb
y 
th
e 
I 5
0 
an
d 
he
nc
e 
IC
50
 
v
al
ue
s i
n 
al
l c
as
es
 st
ra
dd
le
d 
th
e 
IC
50
 
v
al
ue
s a
nd
 w
er
e 
in
 h
al
f-l
og
 in
cr
em
en
ts 
(i.
e. 
1, 
3, 
10
,
30
 μM
 e
tc
). T
he
 nu
mb
er 
of 
co
nc
en
tra
tio
ns
 us
ed
 w
ere
 6 
for
 al
l c
om
po
un
ds
 ex
ce
pt 
1 
(E
tO
H)
 (8
 co
nc
en
tra
tio
ns
), 2
 
(8 
co
nc
en
tra
tio
ns
 fo
r b
oth
 E
tO
H 
an
d D
M
SO
), 9
 
(8 
co
nc
en
tra
tio
ns
), 1
0 
(5 
co
nc
en
tra
tio
ns
),
an
d 
1 
(D
M
SO
) (
4 c
on
ce
ntr
ati
on
s, 
wh
ich
 is
 th
e r
ea
so
n w
hy
 th
e v
alu
es 
are
 gi
ve
n a
s a
pp
rox
im
ate
 in
 th
e t
ab
le)
. C
om
bin
ed
 da
ta 
fro
m 
3–
9 e
xp
eri
me
nts
 w
ere
 us
ed
. A
bb
rev
iat
ion
: E
tO
H,
 et
ha
no
l, D
M
SO
,
di
m
et
hy
lsu
lfo
xi
de
.
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Ta
bl
e 
2
In
hi
bi
tio
n 
of
 c
yc
lo
xy
ge
na
se
 is
of
or
m
s b
y 
co
m
po
un
ds
 1
,
 
2 
an
d 
9
C
om
po
un
d/
C
on
ce
nt
ra
tio
n 
(μM
)
In
iti
al
 a
ct
iv
ity
 (%
 of
 ve
hic
le 
co
nt
ro
l)
C
O
X
-1
 (A
EA
)
C
O
X
-2
 (A
A)
C
O
X
-2
 (A
EA
)
V
eh
ic
le
:
Et
O
H
D
M
SO
Et
O
H
D
M
SO
Et
O
H
D
M
SO
Ib
up
ro
fe
n 
(1)
 
1
90
±1
4 
(3)
10
3±
16
 (3
)
 
3
71
±6
 (6
)
10
4±
8 
(8)
 
10
81
±7
 (3
)
36
±1
7 
(3)
31
±4
 (3
)
 
20
55
±6
 (3
)
78
 (2
)
 
50
35
±9
 (6
)
59
±3
 (3
)
0.
8±
4 
(4)
−
0.
6±
4 
(3)
 
10
0
25
±9
 (6
)
44
±6
 (4
)
88
±4
 (4
)
87
±1
 (3
)
 
20
0
16
±1
8 
(3)
30
±5
 (4
)
 
30
0
64
±8
 (4
)
70
±5
 (3
)
 
50
0
15
±3
 (7
)
Ib
u-
am
5 
(2)
 
3
11
1±
15
 (6
)
 
10
77
±1
0 
(3)
 
20
70
±6
 (3
)
10
6±
15
 (3
)
51
±1
7 
(3)
 
50
57
±0
.6
 (3
)
82
±4
 (6
)
0.
7±
9 
(4)
 
10
0
45
±8
 (3
)
63
±6
 (6
)
88
±8
 (3
)
 
20
0
14
±4
 (3
)
59
±8
 (6
)
 
30
0
59
±4
 (4
)
 
40
0
36
±0
.9
 (3
)
Ib
u-
am
14
 (9
)
3
83
±8
 (3
)
20
76
±8
 (3
)
50
56
±4
 (3
)
−
11
±4
 (3
)
10
0
23
±4
 (3
)
82
±5
 (4
)
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Th
e 
su
bs
tra
te
 u
se
d 
(as
say
 co
nc
en
tra
tio
n 1
0 μ
M
) i
s i
nd
ica
ted
 fo
r e
ac
h C
OX
 is
ofo
rm
. T
he
 in
itia
l a
cti
vit
y (
i.e
. th
e c
ha
ng
e i
n O
2 
co
n
ce
n
tr
at
io
n 
be
tw
ee
n 
10
 a
nd
 3
0 
s a
fte
r a
dd
iti
on
 o
f e
nz
ym
e 
to
 st
ar
t t
he
re
ac
tio
n) 
wa
s d
ete
rm
ine
d a
nd
 th
e v
alu
es 
ca
lcu
lat
ed
 as
 %
 of
 ve
hic
le 
co
ntr
ols
. D
ata
 ar
e s
ho
wn
 as
 m
ea
ns
 ± 
s.e
.m
, w
ith
 th
e n
um
be
r o
f e
xp
eri
me
nts
 gi
ve
n i
n b
rac
ke
ts.
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